GlassScriptPhysician profile
Michael D Slater
NPI 1962451666
$15,193.43
in general payments reported to CMS, 2019-2025
48 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,771 · 2020: $2,368 · 2021: $3,138 · 2022: $2,589 · 2023: $2,109 · 2024: $1,898 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,327.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,730.54 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $1,424.64 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,320.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,161.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $873.62 | 2020-2025 | Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $847.65 | 2019-2025 | Jardiance, Ofev |
| Pfizer INC. | $834.16 | 2019-2025 | |
| Astellas Pharma US INC | $732.22 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $635.05 | 2019-2025 | Xifaxan |
| Amgen INC. | $629.49 | 2019-2024 | Repatha, Otezla |
| Gilead Sciences, INC. | $598.26 | 2019-2025 | Descovy |
| Amarin Pharma, INC. | $352.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $301.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $299.86 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| E.R. Squibb & Sons, L.L.C. | $294.37 | 2021-2025 | Eliquis, Camzyos, Cobenfy |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.